Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Clinuvel Pharmaceuticals Ltd as of April 23, 2024, with changes in relevant interests including securities on loan and purchase and sales as principal/proprietary. The shifts in holdings reflect transactions such as securities lending agreements and proprietary trading, affecting a total of 182,470 ordinary shares. This move may indicate a strategic change in JPMorgan’s investment approach towards Clinuvel.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
